Terms: = Liver cancer AND UBR5, EDD, 51366, ENSG00000104517, EDD1, KIAA0896, HYD, MGC57263, DD5, O95071, FLJ11310 AND Treatment
6 results:
1. pH-Responsive and liver-targeting drug delivery system for combination delivery of artesunate with arsenic trioxide prodrug against hepatocellular carcinoma.
Pan X; Huang J; Liu S; Shao Y; Xi J; He R; Shi T; Zhuang R; Yu W
Drug Dev Ind Pharm; 2023 Aug; 49(8):485-496. PubMed ID: 37470495
[TBL] [Abstract] [Full Text] [Related]
2. Clinicopathological Features and Prognostic Evaluation of ubr5 in liver cancer Patients.
Huo Q; Hu J; Hou B; Zhao M; Han X; Du Y; Li Y
Pathol Oncol Res; 2022; 28():1610396. PubMed ID: 36388433
[No Abstract] [Full Text] [Related]
3. Targeting ubr5 in hepatocellular carcinoma cells and precise treatment via echinacoside nanodelivery.
Wang M; Ma X; Wang G; Song Y; Zhang M; Mai Z; Zhou B; Ye Y; Xia W
Cell Mol Biol Lett; 2022 Oct; 27(1):92. PubMed ID: 36224534
[TBL] [Abstract] [Full Text] [Related]
4. pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects.
Lages EB; Fernandes RS; Andrade MMS; Paiyabhroma N; de Oliveira RB; Fernandes C; Cassali GD; Sicard P; Richard S; Branco de Barros AL; Ferreira LAM
Biomed Pharmacother; 2021 Dec; 144():112373. PubMed ID: 34794238
[TBL] [Abstract] [Full Text] [Related]
5. C2orf40 inhibits hepatocellular carcinoma through interaction with ubr5.
Wu Y; Xiang Q; Lv X; Xiang X; Feng Z; Tian S; Tang J; Xiang T; Gong J
J Gastroenterol Hepatol; 2021 Sep; 36(9):2581-2591. PubMed ID: 33576531
[TBL] [Abstract] [Full Text] [Related]
6. [SCLEROUSIS CHOLANGITIS AT THE AUTOIMMUNE PANCREATITIS PATIENT].
Gavrilina NS; Sedova GA; Kosyura SD; Fedorov IG; Ilchenko LY; Storozhakov G
Eksp Klin Gastroenterol; 2015; (7):78-84. PubMed ID: 26817126
[TBL] [Abstract] [Full Text] [Related]
